drugset / Trial / NCT07521657
Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma
Phase 2
Not yet recruiting
55 enrolled
University of Alabama at Birmingham
Children's Hospital of Philadelphia · collabCongressionally Directed Medical Research Programs · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 2, open label, parallel multi-arm study of mirdametinib in combination with radiation in participants with recurrent sporadic glioblastoma (GBM) harboring NF1 alterations (Cohort 1); participants with NF1 with a newly diagnosed GBM (Cohort 2); mirdametinib alone in other NF1-associated High-Grade Gliomas (Cohort 3).
Timeline
- Start
- 2026-08-01
- Primary completion
- 2030-08-01
- Completion
- 2031-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirdametinib | Small molecule | — | — |